This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://localhost/temp/predkladatel/
n14http://linked.opendata.cz/resource/domain/vavai/projekt/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/resource/domain/vavai/subjekt/
n10http://linked.opendata.cz/ontology/domain/vavai/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F62156489%3A43210%2F12%3A00198376%21RIV13-GA0-43210___/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F62156489%3A43210%2F12%3A00198376%21RIV13-GA0-43210___
rdf:type
skos:Concept n10:Vysledek
dcterms:description
To detect prostate carcinoma, prostatic specific antigen (PSA) is mostly used. However diagnostics of this tumour disease can become more precise using other types of molecules [1]. In this study we aimed at determination of reduced (GSH) and oxidized (GSSG) glutathione and its ratio and level of metallothionein in blood of patients with prostate carcinoma. The obtained results were correlated with PSA levels determined in blood of patients. Analyses were performed in 35 patients with prostate cancer at the age of 54 to 79 years with an average of 66 years and in 8 healthy subjects who formed the control group. PSA levels in patients ranged from 1.4 to 6.4 ng*ml-1 with an average of 2.4 ng*ml-1, GSH/GSSG from 0.6 to 6.7 with an average of 4.3 and metallothionein content ranged from 0.97 to 2.42 uM with an average of 1.91 uM. In the control group PSA values ranged from 0.06 to 0.14 ng*ml-1 with an average of 0.11 ng*ml-1, GSH/GSSG from 7.8 to 13.8 with an average of 9.4 and metallothionein content ranged from 0.51 to 1.04 uM with an average of 0.82 uM. The correlation between PSA and GSH/GSSG reached R2 = 0.378. The value of PSA and metallothionein content was correlated with R2 = 0.589. However, there were observed large differences between the values of the ratio of GSH and GSSG which were significantly (P <0.01) higher in the control group than in the group of patients with prostate cancer. Also, differences in content between metallothionein control group and a group of patients were highly significant (P <0.01). To detect prostate carcinoma, prostatic specific antigen (PSA) is mostly used. However diagnostics of this tumour disease can become more precise using other types of molecules [1]. In this study we aimed at determination of reduced (GSH) and oxidized (GSSG) glutathione and its ratio and level of metallothionein in blood of patients with prostate carcinoma. The obtained results were correlated with PSA levels determined in blood of patients. Analyses were performed in 35 patients with prostate cancer at the age of 54 to 79 years with an average of 66 years and in 8 healthy subjects who formed the control group. PSA levels in patients ranged from 1.4 to 6.4 ng*ml-1 with an average of 2.4 ng*ml-1, GSH/GSSG from 0.6 to 6.7 with an average of 4.3 and metallothionein content ranged from 0.97 to 2.42 uM with an average of 1.91 uM. In the control group PSA values ranged from 0.06 to 0.14 ng*ml-1 with an average of 0.11 ng*ml-1, GSH/GSSG from 7.8 to 13.8 with an average of 9.4 and metallothionein content ranged from 0.51 to 1.04 uM with an average of 0.82 uM. The correlation between PSA and GSH/GSSG reached R2 = 0.378. The value of PSA and metallothionein content was correlated with R2 = 0.589. However, there were observed large differences between the values of the ratio of GSH and GSSG which were significantly (P <0.01) higher in the control group than in the group of patients with prostate cancer. Also, differences in content between metallothionein control group and a group of patients were highly significant (P <0.01).
dcterms:title
Association of PSA level with thiols content in patients with prostate carcinoma Association of PSA level with thiols content in patients with prostate carcinoma
skos:prefLabel
Association of PSA level with thiols content in patients with prostate carcinoma Association of PSA level with thiols content in patients with prostate carcinoma
skos:notation
RIV/62156489:43210/12:00198376!RIV13-GA0-43210___
n10:predkladatel
n11:orjk%3A43210
n4:aktivita
n18:P
n4:aktivity
P(GAP301/10/0356)
n4:cisloPeriodika
1
n4:dodaniDat
n12:2013
n4:domaciTvurceVysledku
n5:3931315 n5:8594716 n5:8541698 n5:9974687 n5:4995775 n5:2307049 n5:8740658 n5:2104237
n4:druhVysledku
n19:J
n4:duvernostUdaju
n6:S
n4:entitaPredkladatele
n17:predkladatel
n4:idSjednocenehoVysledku
123913
n4:idVysledku
RIV/62156489:43210/12:00198376
n4:jazykVysledku
n15:eng
n4:klicovaSlova
glutathion; prostate carcinoma; PSA
n4:klicoveSlovo
n8:prostate%20carcinoma n8:glutathion n8:PSA
n4:kodStatuVydavatele
GR - Řecká republika
n4:kontrolniKodProRIV
[5AB5BC499090]
n4:nazevZdroje
International Journal of Molecular Medicine
n4:obor
n7:CE
n4:pocetDomacichTvurcuVysledku
8
n4:pocetTvurcuVysledku
9
n4:projekt
n14:GAP301%2F10%2F0356
n4:rokUplatneniVysledku
n12:2012
n4:svazekPeriodika
30
n4:tvurceVysledku
Kizek, René Stiborová, Marie Adam, Vojtěch Masařík, Michal Eckschlager, Tomáš Hynek, David Sochor, Jiří Křížková, Soňa Zítka, Ondřej
s:issn
1107-3756
s:numberOfPages
1
n16:organizacniJednotka
43210